GRFS - Grifols acquires 25 U.S.-based plasma centers from BPL

Grifols, S.A. (GRFS) has acquired 25 U.S.-based plasma donation centers from BPL Plasma Inc., a subsidiary of Bio Products Laboratory Holdings Limited.Financed through Grifols’ own resources, the transaction valued at $370M will not necessitate any debt issuance, the company said.With the acquisition which has already received regulatory clearances from the FDA and the UK’s Medicines and Healthcare Products Regulatory Agency ("MHRA"), Grifols will be able to obtain a run-rate of 1M liters of plasma per year.The company with 344 plasma centers worldwide including 289 in the U.S. and 55 in Europe has been able to limit its impact on net plasma supply by 15% in 2020 despite COVID-related constraints.Immunoglobulin therapy providers including Grifols surged in August after the FDA  greenlighted the emergency use of convalescent plasma for COVID-19.

For further details see:

Grifols acquires 25 U.S.-based plasma centers from BPL